Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School, South Korea.
Pain Physician. 2013 Jan;16(1):41-4.
Opioids have been the mainstay analgesics for postoperative, cancerous, and chronic noncancerous pain. Common concerns regarding the use of opioids include the development of physical dependence and addiction. However, as a potential complication of opioid therapy, opioid-induced hyperalgesia (OIH) is often overlooked. That is, patients receiving opioids to control their pain may paradoxically become more sensitive to pain as a consequence of opioid therapy. OIH is a very important issue because it may complicate the clinical course of pain treatment and even worsen the suffering of patients receiving opioids because of the development of excruciating pain. Three OIH types were defined: 1) in the context of maintenance dosing and withdrawal, 2) at very high or escalating doses, and 3) at ultra-low doses. In the literature, most attention has been paid to the first 2 forms, and almost all cases of reported OIH have been ascribed to morphine administration. The third form of OIH has not been documented in humans, although it has been observed in animals. We present 2 cases of OIH resulting from administration of tramadol, which is a synthetic analogue of codeine and exhibits 10-fold less affinity for mu-opioid receptors, in patients suffering from chronic pain. The 2 cases presented herein imply the importance of recognizing OIH in patients medicated with tramadol if analgesic effects are lost in the context of dose titration, when generalized pain is reported without any evidence of disease exacerbation. While OIH associated with ultra-low dose opiates seems to be quite rare, if it is suspected, switching to other drugs and an appropriate treatment should be considered.
阿片类药物一直是术后、癌性和慢性非癌性疼痛的主要镇痛药物。使用阿片类药物常见的担忧包括身体依赖和成瘾的发展。然而,作为阿片类药物治疗的潜在并发症,阿片类药物诱导的痛觉过敏(OIH)常常被忽视。也就是说,接受阿片类药物控制疼痛的患者可能会因为阿片类药物治疗而对疼痛变得更加敏感,这是一种矛盾的现象。OIH 是一个非常重要的问题,因为它可能会使疼痛治疗的临床过程复杂化,甚至会因为剧烈疼痛的发展而使接受阿片类药物治疗的患者的痛苦加剧。OIH 定义了三种类型:1)在维持剂量和停药期间,2)在非常高或递增剂量时,3)在超低剂量时。在文献中,大多数人关注前两种形式,几乎所有报道的 OIH 病例都归因于吗啡给药。第三种形式的 OIH 尚未在人类中记录,但在动物中已经观察到。我们报告了 2 例曲马多给药引起的 OIH 病例,曲马多是可待因的合成类似物,对μ-阿片受体的亲和力低 10 倍,患者患有慢性疼痛。本文报告的 2 例病例表明,如果在剂量滴定过程中失去镇痛效果,或者在没有任何疾病恶化迹象的情况下报告全身性疼痛时,应注意识别接受曲马多治疗的患者中的 OIH。虽然与超低剂量阿片类药物相关的 OIH 似乎很少见,但如果怀疑存在这种情况,应考虑改用其他药物和适当的治疗。